Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust begins Cohort 3 dosing in Phase 1/2 motor neurone disease trial
Health & Biotech
PharmAust flags ‘steady state’ levels in Motor Neurone Disease clinical trial
Health & Biotech
PharmAust confirms safety of MPL, poised to up dosage in MND trial
News
In Case You Missed It: Lithium, rare earth and pharma players do the heavy lifting
Health & Biotech
mTOR drug shows reverse ageing may be possible. Here’s where it puts ASX-listed PharmAust
Health & Biotech
PharmAust’s interim analysis to point the way forward for MND trial
Health & Biotech
PharmAust says its MPL drug has a long and stable shelf life
News
Market Highlights: Wall Street sweat on debt ceiling, CPI; and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSW
Health & Biotech
PharmAust’s MPL drug shows anti-cancer effects across multiple cancer types
News
Market Highlights: Markets brace for more headwinds, and 5 ASX small caps to watch on Tuesday
Health & Biotech
PharmAust’s oversubscribed $2.5m placement highlights investor backing
Health & Biotech
PharmAust delivers positive motor neurone disease Phase-1/2 trial update, giving hope to sufferers with drug well-tolerated
News
Market Highlights: Wall Street surges as Big Tech blows through forecasts; and 5 ASX small caps to watch today
Health & Biotech
PharmAust’s dog trial shows 30pc reduction in cancer tumour, increased quality of life
News
Market Highlights: Tesla crashes 10pc, SpaceX rocket explodes, and 5 ASX small caps to watch on Friday
News
